This is a Phase III study is for patients that have been diagnosed with with early-stage non-small cell lung cancer. The primary purpose of this study is to see if there is a difference in overall survival rate in patients changes based on when they start their drug treatment, either before or after surgical intervention. Participants in this study can expect to be followed for up to 10 years. This study has two groups and a computer will be used to assign study groups. Participants will be randomly assigned to receive either neoadjuvant therapy followed by surgery and adjuvant therapy, or surgery followed by adjuvant therapy. This is called randomization. Patients will have an equal chance of being in either group, similar to flipping a coin.

This study is for adult patients that have been diagnosed with stage I non-small cell lung cancer (NSCLC). The purpose of this study is to evaluate whether a drug called cemiplimab, used in combination with other standard therapies (chemotherapy) is safe and effective in treating early stage NSCLC. Cemiplimab is a FDA approved drug, but its use in this study is investigational. Participants will undergo standard procedures such as blood collection for laboratory testing, physical exams, and imaging. In addition to standard of care treatment, blood will be collected for research purposes and cemiplimab will be administered. Risks of being in this study include side effects from the drugs (such as nausea, vomiting, and low blood counts), loss of confidentiality, and bruising and/or bleeding from blood draws. Participation in this study is expected to last approximately five (5) years.